BR112021026876A2 - Métodos para o tratamento do câncer - Google Patents

Métodos para o tratamento do câncer

Info

Publication number
BR112021026876A2
BR112021026876A2 BR112021026876A BR112021026876A BR112021026876A2 BR 112021026876 A2 BR112021026876 A2 BR 112021026876A2 BR 112021026876 A BR112021026876 A BR 112021026876A BR 112021026876 A BR112021026876 A BR 112021026876A BR 112021026876 A2 BR112021026876 A2 BR 112021026876A2
Authority
BR
Brazil
Prior art keywords
methods
treating cancer
cancer
therapeutic
drug
Prior art date
Application number
BR112021026876A
Other languages
English (en)
Portuguese (pt)
Inventor
Rongrong Jiang
Vaishali Dixit
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112021026876A2 publication Critical patent/BR112021026876A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021026876A 2019-07-01 2020-07-01 Métodos para o tratamento do câncer BR112021026876A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869389P 2019-07-01 2019-07-01
PCT/US2020/040515 WO2021003279A1 (en) 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound e7766

Publications (1)

Publication Number Publication Date
BR112021026876A2 true BR112021026876A2 (pt) 2022-02-22

Family

ID=71895194

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026876A BR112021026876A2 (pt) 2019-07-01 2020-07-01 Métodos para o tratamento do câncer

Country Status (10)

Country Link
US (1) US12564600B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993809B1 (cg-RX-API-DMAC7.html)
JP (1) JP7704690B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220029717A (cg-RX-API-DMAC7.html)
CN (1) CN114599374A (cg-RX-API-DMAC7.html)
AU (1) AU2020300543A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145824A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022000052A (cg-RX-API-DMAC7.html)
WO (1) WO2021003279A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4398901A1 (en) 2021-09-09 2024-07-17 Eisai R&D Management Co., Ltd. Biomarkers for sting agonists and methods of using the same
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446893A1 (en) 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
WO2013169616A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmacokinetic modulation with alisporivir
BR112017018861A2 (pt) 2015-03-04 2018-04-24 Board Of Regents, The Unibersity Of Texas System métodos para tratar câncer mantendo perda hemizigótica de tp53
MX2018010850A (es) 2016-03-10 2019-05-15 Univ Johns Hopkins Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2019004466A1 (ja) 2017-06-30 2019-01-03 興和株式会社 医薬
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Also Published As

Publication number Publication date
AU2020300543A1 (en) 2022-02-24
CA3145824A1 (en) 2021-01-07
JP2022538898A (ja) 2022-09-06
EP3993809B1 (en) 2024-10-09
US20220304982A1 (en) 2022-09-29
EP3993809A1 (en) 2022-05-11
MX2022000052A (es) 2022-04-06
CN114599374A (zh) 2022-06-07
JP7704690B2 (ja) 2025-07-08
WO2021003279A1 (en) 2021-01-07
US12564600B2 (en) 2026-03-03
KR20220029717A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
JOP20220008A1 (ar) مثبطات parp1
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
BR112022003543A2 (pt) Inibidores de kras g12
BR112015027951A8 (pt) arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
MX2019011221A (es) Terapia de combinacion para el tratamiento o prevencion de tumores.
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
MX2018011811A (es) Apositos para heridas modificados.
BR112016011949A8 (pt) composto, composição farmacêutica, e, uso dos mesmos”
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
BR112015016796A8 (pt) modulador de receptor de androgênio, composição farmacêutica que os compreende e usos do mesmo
BR112012013508A2 (pt) pirazolopirimidinas e heterociclos relacionados como inibidores de ck2
CO2024009571A2 (es) Inhibidores de parp1
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
MX2021010152A (es) Moduladores de la expresion de malat1.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
BR112016007410A2 (pt) liberação lenta de conjugados de sn 38
EP4410373A3 (en) Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene
CO2019011538A2 (es) Compuesto macrocíclico y sus usos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]